Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHPS | P49366 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29770374 | 0.90 | DHPS (0.58) | DHPS | |
| SCHEMBL618135 | 0.90 | DHPS (0.58) | DHPS | |
| SCHEMBL5097965 | 0.87 | DHPS (0.56) | DHPS | |
| SCHEMBL7209693 | 0.86 | DHPS (0.58) | DHPS | |
| SCHEMBL30410967 | 0.85 | DHPS (1.00) | DHPS | |
| SCHEMBL7795451 | 0.85 | DHPS (0.53) | DHPS | |
| SCHEMBL28573132 | 0.85 | DHPS (1.00) | DHPS | |
| SCHEMBL4061454 | 0.84 | DHPS (0.83) | DHPS | |
| SCHEMBL1257596 | 0.84 | DHPS (0.52) | DHPS | |
| SCHEMBL7698527 | 0.83 | DHPS (0.65) | DHPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322624-B1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-21 | — | — | EP | disclosed |
| US-7323465-B2 | Alkansulfonamides as endothelin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-01-29 | — | — | US | disclosed |
| US-7091201-B2 | Arylalkane-sulfonamides having endothelin-antagonist activity | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-15 | — | — | US | disclosed |
| US-20050085639-A1 | Novel alkansulfonamides as endothelin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-04-21 | — | — | US | disclosed |
| EP-1465875-A1 | NOVEL ALKANSULFONAMIDES AS ENDOTHELIN ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2004-10-13 | — | — | EP | disclosed |
| US-20040102464-A1 | Arylalkane-sulfonamides having endothelin-antagonist activity | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-05-27 | — | — | US | disclosed |
| WO-2003055863-A1 | NOVEL ALKANSULFONAMIDES AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2003-07-10 | — | — | WO | disclosed |
| EP-1322624-A1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | Actelion Pharmaceuticals Ltd. (CH) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002083650-A1 | NOVEL SULFONYLAMINO-PYRIMIDINES | ACTELION PHARMACEUTICALS LTD (CH) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002024665-A1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2002-03-28 | — | — | WO | disclosed |
| EP-0713875-B1 | Sulfonamides | HOFFMANN LA ROCHE (CH) | 2001-03-21 | — | — | EP | disclosed |
| US-5837708-A | CARDIOVASCULAR DISORDERS OF HYPERTENSION, ISCHEMIA, ANGINA PECTORIS AND VASOSPASMS | HOFFMANN-LA ROCHE INC. (US) | 1998-11-17 | — | — | US | disclosed |
| WO-1996016963-A1 | SULFONAMIDES AND THEIR USE AS MEDICAMENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-06 | — | — | WO | disclosed |
| EP-0713875-A1 | Sulfonamides | F. Hoffmann-La Roche AG (CH) | 1996-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085639-A1 | Novel alkansulfonamides as endothelin antagonists | EDNRA, EDNRB, ECE1 | DHPS 2156/4885 |
| US-20040102464-A1 | Arylalkane-sulfonamides having endothelin-antagonist activity | EDNRA, EDNRB, ECE2 | DHPS 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.